Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status

Prognostic Value of CTNNB1 Gene Mutation in Primary Sporadic Aggressive Fibromatosis

(2014) Danique L. M. van Broekhoven et al.   ANNALS OF SURGICAL ONCOLOGY

A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis

(2014) Jae-Cheol Jo et al.   INVESTIGATIONAL NEW DRUGS

Wait-and-See Policy as a First-Line Management for Extra-Abdominal Desmoid Tumors

(2014) Sylvain Briand et al.   JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME

CTNNB1 S45F Mutation Predicts Poor Efficacy of Meloxicam Treatment for Desmoid Tumors: A Pilot Study

(2014) Shunsuke Hamada et al.   PLoS One

Nuclear expression of β-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors

(2014) Shunsuke Hamada et al.   TUMOR BIOLOGY

Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group

(2013) A. Gronchi et al.   ANNALS OF ONCOLOGY

CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence

(2013) Chiara Colombo et al.   CANCER

Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study

(2013) Stephen X. Skapek et al.   PEDIATRIC BLOOD & CANCER

Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG)

(2011) D. Garbay et al.   ANNALS OF ONCOLOGY

Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis

(2011) M. M. Gounder et al.   CLINICAL CANCER RESEARCH

Prognostic Factors Influencing Progression-Free Survival Determined From a Series of Sporadic Desmoid Tumors: A Wait-and-See Policy According to Tumor Presentation

(2011) Sébastien Salas et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up

(2010) N. Penel et al.   ANNALS OF ONCOLOGY

High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management

(2010) J Dômont et al.   BRITISH JOURNAL OF CANCER

Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial

(2010) R. Chugh et al.   CLINICAL CANCER RESEARCH

Successful Treatment With Meloxicam, a Cyclooxygenase-2 Inhibitor, of Patients With Extra-Abdominal Desmoid Tumors: A Pilot Study

(2009) Yoshihiro Nishida et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic factors for extra-abdominal and abdominal wall desmoids: A 20-year experience at a single institution

(2009) Kai Huang et al.   JOURNAL OF SURGICAL ONCOLOGY

Specific Mutations in the β-Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid Tumors

(2008) Alexander J.F. Lazar et al.   AMERICAN JOURNAL OF PATHOLOGY

Surgical treatment for local control of extremity and trunk desmoid tumors

(2008) Yoji Shido et al.   ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients

(2007) S. Bonvalot et al.   EJSO